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Abstract
Bipolar disorder (BD) is a serious mental illness with substantial common variant heritability. However, the role of rare
coding variation in BD is not well established. We examined the protein-coding (exonic) sequences of 3,987 unrelated
individuals with BD and 5,322 controls of predominantly European ancestry across four cohorts from the Bipolar
Sequencing Consortium (BSC). We assessed the burden of rare, protein-altering, single nucleotide variants classified as
pathogenic or likely pathogenic (P-LP) both exome-wide and within several groups of genes with phenotypic or biologic
plausibility in BD. While we observed an increased burden of rare coding P-LP variants within 165 genes identified as BD
GWAS regions in 3,987 BD cases (meta-analysis OR= 1.9, 95% CI= 1.3–2.8, one-sided p= 6.0 × 10−4), this enrichment
did not replicate in an additional 9,929 BD cases and 14,018 controls (OR= 0.9, one-side p= 0.70). Although BD shares
common variant heritability with schizophrenia, in the BSC sample we did not observe a significant enrichment of P-LP
variants in SCZ GWAS genes, in two classes of neuronal synaptic genes (RBFOX2 and FMRP) associated with SCZ or in
loss-of-function intolerant genes. In this study, the largest analysis of exonic variation in BD, individuals with BD do not
carry a replicable enrichment of rare P-LP variants across the exome or in any of several groups of genes with biologic
plausibility. Moreover, despite a strong shared susceptibility between BD and SCZ through common genetic variation, we
do not observe an association between BD risk and rare P-LP coding variants in genes known to modulate risk for SCZ.
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Bipolar disorder (BD) is a serious mental illness affecting
more than 48 million adults worldwide with a lifetime
prevalence of 1–3% [1, 2]. BD is characterized by extreme
episodes of mood elevation and depression, along with
disturbances in thinking and behavior that often result in
significant disability [3]. The high lifetime morbidity of BD
and frequent suboptimal outcomes with available treatments
present an urgent need to better understand the pathogenesis
of BD. Prior studies have suggested a role for dysregulated
neuronal signaling and synaptic plasticity [4–7], as well
as pathways that regulate neurotransmitter function, neu-
ronal development, and oxidative stress [8, 9]. However, a
comprehensive characterization of biologic mechanisms
in BD remains elusive. A better understanding is critical
for development of effective therapies and personalized
care.
BD is highly heritable (59–93%) within families, and
monozygotic twins show higher concordance rates
(40–80%) than dizygotic twins (5–30%) [10–14]. Genome-
wide association studies (GWAS) have identified over 30
loci that contribute to BD susceptibility, implicating genes
that encode ion channels, neurotransmitter transporters, and
synaptic components [15–18]. Genes implicated by GWAS
might also harbor rare variants [19–21], however this has
not been studied in BD. Whole-exome sequencing (WES)
in BD families has examined the role of rare exonic varia-
tion influencing BD risk. [22–26]. However, these studies
have been small (discovery cohort <200 BD cases) [22–25],
are single-cohort studies [22, 25], and only provide modest
evidence implicating rare coding variants [23, 24, 26].
Overall, it remains unclear whether rare genetic variation
significantly influences risk of BD.
BD shares clinical features and genetic susceptibility
with schizophrenia (SCZ) [12, 18, 27–29], particularly
through common genetic variation. In addition to the
observation that BD and SCZ share a high genetic corre-
lation due to common variation [30], the SCZ polygenic
risk score (PRS) is associated with psychosis in BD, and the
BD PRS is associated with manic behavior in schizophrenia
[28, 31]. Studies of rare variation show that individuals with
SCZ carry a higher burden of ultra-rare protein-altering
variants across the exome, particularly in genes that are
evolutionarily conserved, in genes that affect neuronal
synaptic function, and that have been implicated through
studies of de novo variation in SCZ and autism spectrum
disorder [32–36]. Rare variants in these gene classes have
not been systematically examined in BD. Despite the shared
susceptibility between BD and SCZ through common
genetic variation, it remains unknown whether rare variants
in genes implicated in SCZ contribute to BD.
This study aims to test whether rare, functional protein-
altering variation impacts susceptibility to BD. To this end,
we examined the protein-coding sequences (exomes) of
3,987 individuals with BD and 5,322 healthy controls of
predominantly European ancestry recruited across four
studies to address the following questions: do individuals
Table 1 Bipolar disorder sequencing cohorts.




P-LP SNVs Exonic SNVs Exonic coverage:
median (25–75%)
BRIDGESa US-Caucasian 3,556 1712/1844 32.4 100/0/0 4,812 680,910 8 (6–11)
RareBLISS US-Caucasian 2,000 961/1039 53.0 90.8/0/9.2 3,394 465,504 78 (42–101)
Sweden Swedish-
Caucasian
2,787 831/1956 53.8 65.8/30.3/0.4/1.7/
1.8
1,945 328,066 28 (24–37)
KPNC-EUR US-Caucasian 384 192/192 71.6 100/0/0 511 108,307 34 (22–51)
KPNC-AFR US-African
American
191 96/95 71.2 100/0/0 308 132,872 39 (25–57)
KPNC-LAT US-Latino 198 98/100 72.7 100/0/0 298 101,368 40 (26–60)
KPNC-EAS US-East Asian 193 97/96 63.7 100/0/0 334 88,884 39 (26–58)
All 9,309 3987/5322 47.1 90.6/6.3/2.3
0.4/0.4
9,883 1,328,324
We examined protein-coding (exome) sequence data in 9309 individuals of predominantly European ancestry from four independent studies. Cases
and controls were recruited at ~1:1 ratio except in the Sweden cohort (~1:2 cases to controls). The Kaiser Permanente Northern California (KPNC)
cohort was comprised of four race/ethnicity groups: 40% non-Hispanic white, 20% African American, 20% Latino, and 20% East Asian. The
number of unique exon variants (including exonic, splicing, and 3’ and 5’ UTR regions) is listed for each cohort and across studies.
SNV single nucleotide variant, WES whole-exome sequencing, BRIDGES Bipolar Research in Deep Genome and Epigenome Sequencing Study,
RareBLISS Rare Bipolar Loci Identification through Synaptome Sequencing, EUR European ancestry, AFR African American ancestry, LAT
Latino ancestry, EAS East Asian ancestry, B1D bipolar 1 disorder, B2D bipolar 2 disorder, SAB Schizoaffective disorder, bipolar type, NOS No
otherwise specified, Miss missing specific diagnosis.
aWhole-genome sequencing was performed in BRIDGES. Exome sequencing was performed in all other BSC cohorts.
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with BD carry a greater burden of rare functional coding
variants (1) in their exomes overall; (2) in genes implicated
by common variant GWAS in BD; and (3) in genes
implicated through common and rare variant studies in
SCZ, including neuronal synaptic and loss-of-function
intolerant genes. We subsequently attempted replication of
positive findings in an additional 9,929 individuals with BD
and 14,018 matched controls.
Methods
Cohorts
The study protocol for the combined analysis was approved
by the Johns Hopkins University Institutional Review
Board. All human studies were approved by each respective
institutional ethics review committee, and all participants
provided written informed consent. We examined the
exomes of 3,987 individuals with BD (3,615 with bipolar 1
disorder (B1D), 252 with bipolar 2 disorder (B2D), 91 with
schizoaffective disorder bipolar type (SAB)) and 5,322
unaffected individuals from four case-control cohorts of
predominantly European ancestry that comprise the Bipolar
Sequencing Consortium (BSC) (Table 1, Figs. S1, S2, and
Supplemental Methods). These included 1,712 cases and
1,844 controls from the Bipolar Research in Deep Genome
and Epigenome Sequencing (BRIDGES) study [37], 961
cases and 1,039 controls from the Rare Bipolar Loci Iden-
tification Through Synaptome Sequencing (RareBLISS)
study (NIMH Genetics Initiative repository) [26], 831 cases
and 1,956 controls from Sweden (Swedish National Hos-
pital Discharge Register and population-based registries),
and 483 cases and 483 matched controls from the Kaiser
Permanente Northern California (KPNC) cohort (Multi-
ethnic Genome-wide Study of Bipolar1 Disorder and
Resource for Genetic Epidemiology Research in Adult
Health and Aging (GERA) cohort [38]). All studies were
comprised of individuals of European ancestry except for
KPNC, which included individuals of European (EUR, 192
cases, 192 controls), African American (AFR, 96 cases, 95
controls), Latino (LAT, 98 cases, 100 controls), and East
Asian (EAS, 97 cases, 96 controls) ancestry.
Sequencing and quality control
Whole-genome sequencing (WGS) was performed in the
BRIDGES cohort using the Illumina HiSeq 2500 system.
Library preparation was performed using Nimblegen Seq-
Cap EZ Exome (RareBLISS and KPNC) or Agilent Sur-
eSelect Human All Exon v2 kit (Sweden), and whole-
exome sequencing (WES) was performed using Illumina
HiSeq 2000 or 2500 systems in RareBLISS, Sweden, and
KPNC. Paired sequence reads were aligned to the human
reference build hg19 using BWA [39]. Variant calling was
performed using the GotCloud sequence analysis pipeline
[40] for WGS data in BRIDGES, and joint variant calling
was performed using the Genome Analysis ToolKit
(GATK) [41] for WES data within each of RareBLISS,
Sweden, and KPNC. Genotypes with low sequence cover-
age or poor call quality were removed. Samples that were
identified as population outliers, duplicates or relatives, or
that failed study-specific sequencing metrics were removed.
Variants with high missingness across samples, poor aver-
age genotyping quality, or found to significantly deviate
from Hardy-Weinberg equilibrium were removed. A full
description of sequencing and data quality control is pro-
vided in Supplemental Materials.
Variant selection and annotation
Analysis was limited to single nucleotide variants (SNVs)
that are bi-allelic and whose minor allele matched the
alternative (non-reference) allele. Annotation of all variants
identified from exome and genome sequencing was
done using ANNOVAR, and pathogenicity was assigned
according to 2015 American College of Medical Genetics
(ACMG) criteria using InterVar, a computational imple-
mentation of expert panel recommendations for
clinical interpretation of genetic variants (ACMG 2015 cri-
teria) [42–44]. ACMG classification categories include
pathogenic (P), likely pathogenic (LP), variant of uncertain
significance, likely benign, and benign. Variants that were
rare (maximum population-specific minor allele frequency
[MAF] < 1% in the Genome Aggregation Database [gno-
mAD] [45, 46]), protein-altering (missense, splice site,
stopgain, startloss, stoploss (none observed), and classified
as pathogenic or likely pathogenic by InterVar were retained
for analysis.
Gene-level burden testing
To assess whether individuals with BD carry a greater burden
of rare pathogenic or likely pathogenic (P-LP) variants in
individual genes, we performed Firth logistic regression on
the number of P-LP alleles within the gene per individual
(adjusted for sex and at least five ancestry principal compo-
nents) for each of seven groups (BRIDGES, RAREBLISS,
Sweden, KPNC-EUR, KPNC-AFR, KPNC-LAT, KPNC-
EAS), followed by a meta-analysis across groups using the
weighted Z-score method. We calculated a one-sided p
value for enrichment of P-PL variants in BD cases from the
meta-analysis Z-score, and used a Holm-adjusted p value <
0.05 to report significant associations.
Investigating rare pathogenic/likely pathogenic exonic variation in bipolar disorder
Gene set selection
We assessed whether exomes of BD patients are enriched
for rare functional protein-altering variants in genes impli-
cated by the largest BD GWAS meta-analysis [18]. We
defined the following three BD-related gene sets: 165 genes
identified by physical proximity to variants in linkage dis-
equilibrium (r2 > 0.1) with BD GWAS-associated variants
(BD GWAS), 153 genes identified using the software
package MAGMA (Multi-marker Analysis of GenoMic
Annotation) [47] on BD GWAS data (BD MAGMA), and
81 genes identified through the intersection of the above
two gene sets (BD MAGMA-GWAS). Given that BD
shares genetic susceptibility with schizophrenia (SCZ)
[12, 18, 27–29], particularly through common genetic var-
iation, we examined genes implicated in a large schizo-
phrenia GWAS (CLOZUK+PGC2) [48] by defining the
following three gene sets: 623 genes identified by variants
in linkage disequilibrium (r2 > 0.1) with schizophrenia
GWAS-associated variants (SCZ GWAS), 550 genes
identified using MAGMA on schizophrenia GWAS data
(SCZ MAGMA), and 342 genes identified through the
intersection of these two gene sets (SCZ MAGMA-GWAS).
Given the strong impact of rare variant burden on SCZ
susceptibility and the partial clinical overlap between BD
and SCZ [34, 48–50], we also examined three gene sets
previously implicated in SCZ rare variant risk:
3,055 synaptic genes whose mRNA are bound by the
splicing factor RBFOX2 [32, 51] (Synaptic-RBFOX2),
1,033 synaptic genes whose mRNA are bound by FMRP
[32, 52] (Synaptic-FMRP), and 3,230 genes classified as
loss-of-function (LOF) intolerant from the large ExAC
dataset [45] (LOF-intolerant).
Gene set burden testing
We used two statistical methods to evaluate whether BD cases
carry a higher burden of rare functional protein-altering var-
iants (described above) than controls for each candidate gene
set. First, we performed meta-analysis of Firth logistic
regressions from each of seven groups described above.
Second, we performed Cochran–Mantel–Haenszel (CMH)
chi-square tests on the P-LP count in cases and controls across
studies, and determined the empirical (one-sided) p value for
enrichment of P-PL variants in BD cases by comparing this
CMH chi-square statistic to a null distribution generated from
a random selection of an equivalent number of genes in
10,000 simulations. We performed these random simulations
to control for potential confounding due to variability in
sample selection and sequencing methods between cases and
controls within each study. We conducted all statistical ana-
lyses in R [53]. See Supplemental Methods for full burden
testing methods.
Replication
We examined exome sequence data in an independent
cohort of 9,929 individuals with BD and 14,018 matched
controls from the Bipolar Exomes (BipEx) collection
(see Supplemental Materials). Of 3,639 BD cases with
known subtypes, 2,684 were classified as B1D, and 955
were classified as B2D. After WES variant calling and
quality control, we annotated exonic variants using Inter-
Var, and extracted all rare (gnomAD maximum population
MAF < 1%), protein-altering (missense, splice site, stop-
gain, startloss) SNVs that were classified as P or LP, as was
done for the BSC studies. Statistical analysis was the same
as used in the BSC analysis. Specifically, we examined the
burden of rare P-LP variants in BD cases versus controls,
and in B1D cases versus controls, within the three BD gene
sets (BD GWAS, BD MAGMA, BD MAGMA-GWAS).
We performed Firth logistic regression on the number of
rare P-LP alleles per individual (adjusted for sex, 10 prin-
cipal components, and the total burden of non-reference
alleles) within each of six cohorts that comprised the BipEx
replication sample (US, UK, Sweden-Umea, Sweden-Kar-
olinska, Netherlands, and Germany), followed by a meta-
analysis across cohorts using the weighted Z-score method.
PRS analysis of common (GWAS) variants
Except for BRIDGES, which used genotypes from WGS,
studies used previously published GWAS array data from
European-descent individuals imputed into the 1000 Gen-
omes or 1000 Genomes + Haplotype Reference Con-
sortium reference panels to select variants for inclusion in
polygenic risk score analysis [18, 38, 54–58]. We identified
the set of variants present and well imputed (imputation R2
or info score >0.5) and with MAF > 0.01 in all studies and
limited to the European ancestry sample in KPNC. We
further filtered variants where any individual cohort fre-
quency deviated from the mean frequency by >0.2, resulting
in a final set of 2,855,373 SNPs for building polygenic
scores.
To generate SNP sets and per SNP weights for building
polygenic scores independent from the data in the current
study, we started with association results from studies that
participated in recent PGC2 analyses for bipolar disorder
[18] and schizophrenia [59], then removed all studies with
participants overlapping with BSC study samples and re-ran
case-control association meta-analysis. These modified
meta-analyses included roughly 11,000 cases and 17,000
controls for bipolar disorder and 19,000 cases and 28,000
controls for schizophrenia. In both the bipolar and schizo-
phrenia association results, we extracted the subset of SNPs
overlapping the high quality BSC variants described above
and identified sets of variants to include in PRS analysis by
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clumping all SNPs based on LD (1MB windows and r2 >
0.1) using 1000 Genomes European individuals as the
reference sample. For each trait, we selected variants at
three different p value thresholds (P < 0.01, <0.05, and
<0.1) to determine the effect of threshold on the strength of
the PRS association with bipolar disorder. Each study then
generated a PRS score for each individual based on geno-
type dosages and using log(OR) from the restricted PGC2
analyses as weights. Each group then tested for association
using logistic regression of the PRS on bipolar case-control
status in their BSC GWAS/WGS data adjusting for sex,
genotype-based principal components, and where neces-
sary, genotype batch. We combined results from all studies
using inverse variance-weighed meta-analysis.




Exome analysis in 3,987 individuals with BD (91% B1D,
6% B2D, and 2% SAB) and 5,322 unaffected individuals
(Table 1, Table S1, Fig. S1) identified 1,328,324 exonic
SNVs that passed quality control, of which 792,375 were
rare (gnomAD maximum population MAF < 1%) and
protein-altering (primarily missense, splice-site, and stop-
gain); 9,883 (0.7%) of exonic SNVs were classified as
pathogenic (P) or likely pathogenic (LP) using InterVar [42]
(Table S2). Variants classified as pathogenic included 2,629
stop-gain and 1,963 splice-site altering SNVs affecting
2,076 genes. Variants classified as likely pathogenic inclu-
ded 5,152 missense, 463 stop-gain, and 1 stop-loss affecting
1,173 genes (Table S2). On average, each individual carried
0.72 pathogenic and 1.2 likely pathogenic SNVs across the
exome. Most (81%) of P-LP variants were singleton
mutations, and a significant proportion (38%) of such var-
iants were not previously reported in the large gnomAD
database (Fig. 1).
The exome-wide burden of rare synonymous variants did
not differ between BD cases and controls (odds ratio [OR]
= 1.00, 95% confidence interval [CI]= 0.9985–1.0004, p
= 0.23), suggesting an absence of exome-wide bias in
detecting rare variants across a heterogeneous group of
sequencing studies. We subsequently restricted our analysis
to rare protein-altering variants classified as pathogenic or
likely pathogenic (P-LP) (Table S2). Examination of gene-
level burden of rare P-LP variants did not reveal any genes
that passed exome-wide significance (Table S3). Likewise,
the exome-wide P-LP burden also did not differ between
BD cases and controls (OR= 1.00, 95% CI= 0.97–1.03, p
= 0.39), differing from sequencing studies of SCZ and
developmental disorders of similar sample size showing an
increased burden of rare coding variants across the exome
[32, 42, 49].
However, BD cases carried a higher burden of P-LP
variants compared to controls within 165 bipolar GWAS
genes (meta-analysis of Firth logistic regressions OR=
1.89, 95% CI= 1.29–2.77, one-sided p= 6.0 × 10−4) and
within 153 bipolar genes identified using MAGMA (meta-
analysis OR= 1.56, 95% CI= 1.11–2.19, one-sided p=
0.0052) (Figs. 2, 3, Tables 2, S4 and S5). The relative
burden of rare P-LP variants was higher within 81 genes
representing the intersection of these two gene sets (meta-
analysis OR= 2.66, 95% CI= 1.35–5.21, one-sided p=
0.0023) (Figs. 2, 3, Tables 2, S4 and S5). The CMH ana-
lysis results were consistent with those from meta-analysis
of Firth logistic regressions described above and there was
no evidence of heterogeneity in OR among the studies
(Tables S4 and S5 for individual BSC study results). Meta-
analysis results were also broadly consistent when subset to
subjects of European ancestry (Tables S4 and S5).
Attempted replication in WES data from 9,929 BD cases
and 14,018 controls (Table S6) from the BipEx collection
did not reproduce the observed enrichment of rare P-LP
variants within the BD GWAS (meta-analysis OR= 0.94,
one-sided p= 0.70), BD MAGMA (OR= 0.87, p= 0.87),
or BD MAGMA-GWAS (OR= 0.64, one-sided p= 0.95)
gene sets (Fig. 3, Table S7). Similarly, examination of
2,684 B1D-only cases and 14,018 controls did not reveal an
enrichment of rare P-LP variants in the BD GWAS (OR=
0.89, one-sided p= 0.74), BD MAGMA (OR= 0.98, one-
sided p= 0.54), or BD MAGMA-GWAS (OR= 0.85, one-
sided p= 0.65) gene sets (Table S7). Thus, the initial
observed enrichment of rare functional protein-altering
variants within BD GWAS genes was not replicated.
Fig. 1 P-LP variant distribution. Minor allele counts for variants
classified as P or LP from 9,309 individuals in the BSC cohort show
that 81% of P-LP variants are singleton mutations. 38% of P-LP
variants are not present in gnomAD. 44% of such variants are clas-
sified as P (predominantly splice site and nonsense variants), and 56%
are classified as LP (predominantly missense variants). P pathogenic,
LP likely pathogenic, S Splice site, N nonsense, M missense, ACMG
American College of Medical Genetics, GnomAD Genome Aggre-
gation Database.
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Given the shared clinical features and reports of shared
common genetic susceptibility between BD and SCZ, we
also examined the burden of rare P-LP variants for three
schizophrenia-related gene sets. Meta-analysis across
cohorts showed no significant enrichment of rare P-LP
variants in the 623 SCZ GWAS genes (OR= 1.19, 95% CI
= 1.02–1.39, one-sided p= 0.01, adjusted one-sided p=
0.08), in 550 SCZ MAGMA genes (OR= 1.07, 95% CI=
0.89–1.28, one-sided p= 0.24), and in 342 SCZ MAGMA-
GWAS genes (OR= 1.11, 95% CI= 0.94–1.32, one-
sided p= 0.12) (Fig. 2, Tables 2, S4 and S5). CMH analysis
again showed results similar to meta-analysis with Firth
logistic regression (Tables 2 and S4). This suggests that
despite the shared common genetic susceptibility between
BD and SCZ, we found no evidence for BD risk being
associated with rare functional protein-altering variation in
schizophrenia GWAS genes.
We examined three gene sets previously reported to
harbor rare variants that influence neuropsychiatric traits:
3,055 genes whose mRNAs are bound by the synaptic
protein RBFOX2, 1,233 FMRP-related genes that co-
localize with neuronal synapses, and 3,230 genes reported
to be intolerant to loss-of-function mutations. Each of these
gene sets has been implicated in rare variant studies of
schizophrenia [26, 32, 34, 50, 52]. We observed no sig-
nificant enrichment of rare P-LP variants in the RBFOX2-
related genes (meta-analysis OR= 0.99, 95% CI=
0.98–1.01, one-sided p= 0.86), FMRP-related genes (OR
= 0.93, 95% CI= 0.82–1.04, one-sided p= 0.91), or LOF-
intolerant genes (OR= 0.94, 95% CI= 0.86–1.02, one-
sided p= 0.94) in BD cases versus controls across studies
(Fig. 3). CMH analysis confirmed a lack of rare variant
enrichment within these gene sets (Table 2), thus we had no
evidence of BD risk from rare functional protein-altering
variants in a broad set of genes encoding proteins that
localize to neuronal synapses, that were previously asso-
ciated with schizophrenia.
Lastly, we used published PGC2 case-control GWAS
meta-analysis results for BD and schizophrenia to test the
common polygenic burden on risk of BD in our BSC
subjects. Consistent with previous publications [60], com-
mon variant PRS for both BD and schizophrenia were
highly significant in the combined meta-analysis (pBD=
1.52 × 10−41 and pSZ= 1.51 × 10−32, Table S8), but
explained only a small proportions of variance in disease
risk (~1–4%) in individual BSC studies, again demonstrat-
ing the shared genetic etiology of these psychiatric condi-
tions, at least from common variants and in contrast to rare
variant analyses.
Discussion
To our knowledge, this primary analysis of 3,987 BD cases
and 5,322 controls, along with independent replication/sec-
ond stage samples of 9,929 cases and 14,018 controls
represents the largest study of coding sequence variation in
BD. We examined the exomes of these individuals, and
identified rare coding variants classified as P-LP according
to ACMG criteria [42, 44]. We did not observe a significant
enrichment of rare P-LP variants in BSC BD cases versus
controls overall or for any individual gene. We also did not
observe an increased burden of rare P-LP variants in genes
implicated by BD GWAS regions in the combined BSC and
BipEx cases. This observation diverges from studies in some
other complex disorders that found an enrichment of rare
coding variation in genes associated with GWAS loci
identified from common variants and vice versa [19–21, 61].
We did not observe a difference in rare P-LP variant
burden within gene sets that influence synaptic function
Fig. 2 P-LP variant burden in candidate BD- and SCZ-related
gene sets. Meta-analysis of Firth logistic regression of P-LP variants
shows that BD cases in BSC cohorts appear to carry a higher burden of
P-LP alleles in three BD GWAS-derived gene sets. Horizontal bars
represent 95% confidence intervals. No enrichment of P-LP variants
was observed in three schizophrenia GWAS-derived gene sets, in two
neuron synaptic-related genesets (RBFOX2- and FMRP-related
genes), in genes classified as LOF-intolerant, or in all genes across
the exome. P values are one-sided for enrichment of P-PL variants in
BD cases and derived from the meta-analysis Z-score. Numbers in
parentheses represent the number of genes with P-LP variants and total
number of genes within each gene set, respectively. BD bipolar dis-
order, OR odds ratio, P-LP pathogenic or likely pathogenic, GWAS
genome-wide association study, LOF loss-of-function.
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(RBFOX2 and FMRP), genes that are intolerant to loss-of-
function mutations, or all genes across the exome. This
diverges from prior studies of exonic variation in familial
BD cases that suggest a role for synaptic-related genes [25],
ion channels [23], and modulation of neurotransmitter
activity [24]. However, those studies were small (far smaller
than ours) and their findings unreplicated, highlighting the
need for large studies with replication cohorts. While this
study was not powered to identify novel single gene asso-
ciations, it provides important insight into the genetic
architecture of rare coding variants in BD, specifically the
absence of replicable enrichment of such variants in several
biologically plausible gene sets.
A shared genetic susceptibility to BD and SCZ is sug-
gested through investigations of genome-wide common
variation and polygenic risk scores (PRS) [12, 27–29]. Our
results confirmed the correlation of common SCZ variants
with BD risk. Moreover, examination of sub-phenotypes
suggests that the SCZ PRS is associated with psychosis in
BD, and that the BD PRS is associated with mania in SCZ
[23, 24]. However, examination of rare coding variation
does not support a clear role for BD-related genes in SCZ
risk [32]. Similarly, we observe no significant enrichment of
rare P-LP variants within SCZ GWAS genes in individuals
with BD, or in other gene sets (RBFOX2, FMRP, LOF-
intolerant, exome-wide) that have been reported to harbor
rare variants in SCZ [32, 35]. While larger studies might
reveal a smaller effect within these broader gene sets, this
study does not show a clear role for rare variants within
SCZ-related genes in BD.
The absence of deleterious rare variant enrichment in BD
cases contrasts to studies of SCZ of similar size (4–5 K
cases, 7–9 K controls) which show that individuals with
SCZ carry an increased burden of rare protein-truncating
variants across the exome, particularly in genes intolerant to
loss-of-function mutations [32, 35]. This burden was par-
ticularly elevated in SCZ cases with intellectual disability
[35]. Another study showed that rare CNVs are enriched in
individuals with schizoaffective disorder bipolar type
(SAB), but not in all individuals with BD [62]. These
observations suggest that, while there exists a shared sus-
ceptibility for BD and SCZ through common genetic var-
iation, rare coding variation in gene sets implicated in SCZ
might preferentially confer a risk for SCZ-specific features
independent of the affective symptoms that are definitional
of BD. Thus, individuals with rare variants in genes
implicated in SCZ might present with psychotic or cogni-
tive predominant symptoms, rather than manic or hypo-
manic episodes, which are required for a diagnosis of BD.
In this study, variants classified as pathogenic are loss-of-
function (LOF) mutations (splice-site and stop-gain) in a
gene where LOF is a known mechanism of disease, while
those classified as likely pathogenic are primarily missense
variants in a gene with a low rate of benign missense var-
iation. Both types of variants are absent or at very low
frequency in large control cohorts (gnomAD), and have
Fig. 3 P-LP variant burden in BD GWAS gene sets within BSC
discovery and BipEx replication cohorts. Forest plots of log odds
ratios (Firth logistic regressions) for association between P-LP variant
burden and BD across seven cohorts/ethnicities in the BSC study (top)
and across six strata in the BipEx replication cohort (bottom). p values
are one-sided for enrichment of P-PL variants in BD cases and derived
from the meta-analysis Z-score. Meta-analysis shows that individuals
with BD do not carry a replicable enrichment of P-LP variants in 165
BD GWAS-derived genes, in 153 BD genes identified using
MAGMA, or in 81 genes that overlap between the BD GWAS and BD
MAGMA gene sets. Horizontal black lines indicate 95% confidence
intervals around the effect size. Unshaded boxes indicate absence of P-
LP variants within a specific cohort. Gray boxes indicate meta-analysis
within the BSC (discovery) and BipEx (replication) cohorts, respec-
tively, and black box indicates meta-analysis across all BSC and
BipEx cohorts. Numbers in parentheses indicate the number of BD
cases and controls. BSC Bipolar Sequencing Consortium, BipEx
Bipolar Exomes collection, REP replication cohorts, META meta-
analysis.
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multiple lines of evidence for a deleterious effect. While
there are likely a number of P-LP variants not included as P-
LP in our study (e.g., frameshift LOF variants), their non-
inclusion would only have limited the power of our ana-
lysis, and not created a bias. Nonetheless, examination of
the P-LP variants we included did enable systematic inter-
rogation of candidate gene sets that might be biologically
relevant for a complex phenotype such as BD.
Although we found three significantly associated gene-
sets in our BSC study, these genesets did not replicate in the
BipEx study and they were not significant in a meta-
analysis of the BSC and BipEx studies. There are differ-
ences in the case composition of the BSC and BipEx
samples. More BD cases were classified as B1D, a form of
BD with more extreme episodes of mood elevation [63], in
the BSC discovery cohort (91% of cases) than in the BipEx
replication cohort (74% of cases with known subtypes),
However, when restricting to the smaller set of BipEx B1D
cases we still did not detect association in the genesets
identified in the BSC studies. It may be that the BSC
geneset-based results are false positives or that larger
sample sizes with deleterious variants defined by other
metrics may be necessary to consistently detect a signal.
We acknowledge a number of limitations. First, there are
a number of inter-study differences in methods used for
case-control selection, DNA sample acquisition, exome or
genome sequencing, and data quality control. While these
differences might contribute to biases in variant detection in
cases and controls, we showed that our approach produced
no exome-wide deviation of rare synonymous variants in
cases versus controls. Second, our analysis was limited to
coding single nucleotide variants, which have the highest
quality annotation in large public databases (gnomAD) and
annotation tools (InterVar). Future WGS studies that
include analysis of copy number, insertion-deletion, and
regulatory variants may shed further light on the role of rare
variants in BD. Third, while genome-wide common variant
studies implicate loci that influence susceptibility for BD,
many genes in these regions that were included in our
analysis are likely unrelated to BD, highlighting the need
for fine-mapping and functional studies. Lastly, our ability
to further investigate the observed differences between the
discovery and replication cohorts was limited due to the
lack of deep sub-phenotype data (such as severity of mood
episodes, psychosis, hospitalizations) in the majority of
BD cases.
Despite the limitations, this study provides important
biologic insight into disease pathogenesis in BD. While
common and rare variant associations implicate several
genes critical for neuronal development and synaptic
function [15–18, 22–26], this study suggests that BD risk
may not be broadly influenced by rare coding variation in
genes within these categories. Moreover, while common
genetic association studies suggest a role for shared
genetic susceptibility between BD and SCZ, there is
limited evidence for a shared susceptibility from rare
genetic variation for these related mental disorders.
Additional studies are needed to dissect the relationship
between rare coding variants and subtypes of BD,
including SAB. Neuroimaging and neurophysiological
biomarkers [64, 65] may be used to identify genetic fac-
tors that influence endophenotypes within these complex
Table 2 Rare variant burden in candidate gene sets.
Gene sets examined Meta-analysis of Firth logistic regressions
Gene set Genes P-LP count OR (95% CI) One-sided p value Adjusted p value
All Carrying P-LP variants 3987 cases 5322 controls
BD GWAS 165 35 78 51 1.89 (1.29–2.77) 0.0006 0.006
BD MAGMA 153 29 72 53 1.56 (1.11–2.19) 0.0052 0.042
BD MAGMA-GWAS 81 15 21 8 2.66 (1.35–5.21) 0.0023 0.021
SCZ GWAS 623 111 288 299 1.19 (1.02–1.39) 0.011 0.077
SCZ MAGMA 550 113 282 331 1.07 (0.89–1.28) 0.24 1.00
SCZ MAGMA-GWAS 342 72 198 219 1.11 (0.94–1.32) 0.12 0.72
Synaptic-RBFOX2 3,055 698 1,219 1,555 0.99 (0.98–1.01) 0.86 1.00
Synaptic-FMRP 1,233 413 756 976 0.92 (0.83–1.04) 0.91 1.00
LOF-intolerant 3,230 1,246 1628 2,059 0.93 (0.86–1.02) 0.94 1.00
All genes 25,134 2,634 7,847 9,787 1.00 (0.97–1.03) 0.39 1.00
For each of 10 candidate gene sets, we performed a meta-analysis of the effect of P-LP variant burden on BD within each study (using adjusted
Firth logistic regression), and calculated a one-sided p value examining enrichment of P-LP variants in BD cases. Adjusted p values represent
correction for multiple comparisons using the Holm method.
BD bipolar disorder, SCZ schizophrenia, GWAS genome-wide association study, LOF loss-of-function, OR odds ratio.
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disorders. Lastly, loci identified through BD common
variant studies likely require fine-mapping through func-
tional studies, and not only through scalable genomics
methods, for translational impact.
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